Tumour ablation: current role in the kidney, lung and bone.
Tumour ablation: current role in the kidney, lung and bone.
复制标题
DOI：
10.1102/1470-7330.2009.9028
复制
发表时间：
2009-10-02
期刊：
影响因子：
--
通讯作者：
Gillams A
中科院分区：
文献类型：
--
作者：
Gillams A
在过去的几年里，消融技术的使用和可获得性迅速扩大，发表了数百篇论文。射频技术在成本、设置简便性、通用性和灵活性方面仍处于领先地位，但其他技术正在迎头赶上。由于探头尺寸较大，以前只有在开腹手术中才能使用的冷冻和微波消融，现在很容易进行经皮消融，发病率可预见地降低。消融术现在被认为是不适合移植的有限体积肝细胞癌患者的一线治疗方法。在大多数其他领域，争论仍在继续，但越来越多的证据表明，在肝转移、肾癌、无法手术的肺肿瘤和一些骨肿瘤中发挥了重要作用。
The last few years have seen a rapid expansion in the use and availability of ablation techniques with hundreds of papers published. Radiofrequency remains the front-runner in terms of cost, ease of set-up, versatility and flexibility but other techniques are catching up. Ablation with cryotherapy and microwave, which were previously only available at open laparotomy due to the large size of the probes, are now readily performed percutaneously, with a predictable reduction in morbidity. Ablation is now accepted as the first line of treatment in patients with limited volume hepatocellular carcinoma who are not candidates for transplantation. There is continuing debate in most other areas but the evidence is increasing for an important role in liver metastases, renal carcinoma, inoperable lung tumours and some bone tumours.